Pharmaceutical firms had cast brain drugs aside  opting instead to devote resources to less risky often more lucrative areas of research like oncology and immunology. But recent scientific and technological breakthroughs along with the approvals of new medicines for Alzheimers and ALS have helped renew investor interest in neuroscience